Johan van Walsem, Metabolix COO, has been leading the wind down of the company's biopolymer
operations and transfer of biopolymer
assets to CJ CheilJedang.
With the new space in Woburn, we will be able to upgrade and expand our biopolymer
applications development lab to support customer projects as we continue to ramp up our PHA [polyhydroxyalkanoate] biopolymer
market development activities and work to transition from pilot scale to commercial scale operations.
US-based industrial biotechnology company TerraVerdae BioWorks has entered into a strategic partnership agreement with PolyFerm Canada, a Canadian biopolymer
company focused on developing renewable and biodegradable alternatives to petrochemical-based elastomers, the company said.
Delivery systems consisting of lipid droplets encapsulated by nano-laminated biopolymer
coatings have potential, but there is some concern about the bioavailability of the encapsulated lipids.
They describe biopolymer
modification methods to enhance the compatibility, flexibility, enhanced physicochemical properties, thermal stability, impact response, and rigidity of materials like chitosan, agar-based graft copolymers, lignocellulose fibers, degradable poly(3-hydroxyalkanoates), starches, natural fibers, and cellulose nanocrystals, and tissue engineering and drug delivery, biomedical and environmental, biological, food and non-food, and other applications.
The buzz was about Wintershall's research project about the biopolymer
Chitin is a biopolymer
that comprises a linear sequence of monomeric sugars of Nacetylglucosamine.
Among the topics are biopolymers
from plants, bacterial biopolymers
and genetically engineered biopolymers
for gel systems applications, associating biopolymer
systems and hyaluronate biomaterials, and conformation and rheology of microbial exopolysaccharides.
Adding the Vigido know-how to FMC's newly acquired pectin business provides FMC BioPolymer
with enhanced ability to serve a wide range of low pH food applications.
Neurotrauma treatment company InVivo Therapeutics Holdings Corp (OTC BB :NVIV) revealed on Friday that it ha received approval to begin human studies to test its biopolymer
scaffold product technology to treat patients with acute, traumatic Spinal Cord Injury (SCI).
In addition, biocompatibility of the biopolymer
material is questionable because of the release of toxic components from some of the crosslinkers upon usage.